<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01113567</url>
  </required_header>
  <id_info>
    <org_study_id>2010-785-016</org_study_id>
    <nct_id>NCT01113567</nct_id>
  </id_info>
  <brief_title>Effect of Lactose in Patients With Chronic Liver Disease and Minimal Hepatic Encephalopathy</brief_title>
  <official_title>Effect of Lactose in Patients With Chronic Liver Disease and Minimal Hepatic Encephalopathy. Double- Blind, Randomized, Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two groups of patients with minimal hepatic encephalopathy will be studied. The treatment
      group (n=17) will receive whole milk (24 g lactose) and the control group (n=17) will receive
      &quot;lactose-free&quot; milk (3.5 g of lactose) two times a day for 21 days. Clinical history,
      nutritional assessment, biochemical studies, psychometric tests, critical flicker frequency
      and a quality of life questionnaire will be performed. The patient will be assessed weekly 21
      days. An external monitor will control the randomization process in order to allocate the
      patients into both study group and will not share the assignation codes with anyone until the
      end of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mortality due to chronic liver disease is among the first five causes of mortality related to
      digestive tract and liver diseases in patients on productive age. One of the most frequent
      complications of chronic liver insufficiency is minimal hepatic encephalopathy (MHE), which
      affects the quality of life and predisposes to the development of clinical hepatic
      encephalopathy. There are few evidences on the therapeutic alternatives for minimal hepatic
      encephalopathy. The administration of non-absorbable disaccharides has been proven to
      ameliorate MHE. Lactose maldigestion may justify the use of lactose in patients with chronic
      liver disease as a non-absorbable disaccharide for the treatment of MHE.

      The aim of our study is to evaluate the efficacy of lactose administration in patients with
      minimal hepatic encephalopathy.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    We didn't find differences among both groups
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reversion of Minimal Hepatic Encephalopathy (psychometric test)</measure>
    <time_frame>30 days after intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life and blood ammonium</measure>
    <time_frame>30 days after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Diet and lactose-free milk</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lactose-free milk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet and whole milk</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Whole milk with lactose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactose-free milk</intervention_name>
    <description>3.5 g of lactose</description>
    <arm_group_label>Diet and lactose-free milk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Whole milk</intervention_name>
    <description>Whole milk with 24 g lactose</description>
    <arm_group_label>Diet and whole milk</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of chronic liver disease of whichever etiology

          -  Minimal hepatic encephalopathy

          -  Lactose maldigestion

        Exclusion Criteria:

          -  Patients with clinical manifestations of hepatic encephalopathy

          -  Recent use of antibiotics or psychotropic drugs

          -  Recent use of alcohol abuse

          -  Gastrointestinal bleeding

          -  Others neurological disorders that affect the psychometric test

          -  Chronic renal failure

          -  Congestive heart failure

          -  Chronic Obstructive Pulmonary Disease

          -  Severe symptoms of lactose intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Segundo Moran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Mexicano del Seguro Social</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06725</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.imss.gob.mx</url>
    <description>Instituto Mexicano del Seguro Social</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2010</study_first_submitted>
  <study_first_submitted_qc>April 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2010</study_first_posted>
  <last_update_submitted>August 9, 2016</last_update_submitted>
  <last_update_submitted_qc>August 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Coordinación de Investigación en Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Segundo Moran Villota</investigator_full_name>
    <investigator_title>Asociado B</investigator_title>
  </responsible_party>
  <keyword>Hepatic Encephalopathy</keyword>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>Disaccharides</keyword>
  <keyword>Lactose</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

